This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schneeweiss, S.
Right arrow Articles by Maclure, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schneeweiss, S.
Right arrow Articles by Maclure, M.
Related Collections
Right arrow Other health policy
Right arrow Hypertension
Right arrow Other drug use
CMAJ • July 23, 2002; 167 (2)
© 2002 Canadian Medical Association or its licensors

Letters
Correspondance

Reference drug pricing

Sebastian Schneeweiss*, Stephen B. Soumerai{dagger} and Malcolm Maclure{ddagger}

*Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital and Harvard Medical School, Boston, MA; {dagger}Drug Policy Research Group, Department of Ambulatory Care and Prevention, Harvard Medical School, Boston, MA; {ddagger}School of Health Information Science, University of Victoria, Victoria, BC

In his commentary, Aslam Anis correctly points out that there is a greater need for randomized trials to assess the therapeutic equivalence of prescription drugs within a class.1 However, he misinterpreted our results2 when he stated that the reference drug pricing policy led to a "10% decline in the use of antihypertensives." Due to a temporary reduction in the length of supply of pharmacy dispensings during a 5-month transition period, the non-significant (p = 0.15) dip in dispensings per month is likely to be inconsistent with an underutilization of antihypertensives.3 In Figure 2 of our article it becomes even more obvious that there is no change after the transition period (p = 0.40).2 Furthermore, we found no increase in the rate of discontinuing antihypertensive drug therapy.4 We also found that overall costs, including emergency room and hospital utilization, did not change after the policy.4 The net savings of $6 million in the first year in the elderly alone,4 which amounted to 6% of expenditures for all cardiovascular drugs,5 were much higher than most drug cost-containment policies.6 Overall, this is one of the only drug cost-containment policies (of which we are aware) that saved substantial costs without unintended outcomes on patient health status or use of expensive services.

Sebastian Schneeweiss Division of Pharmacoepidemiology and Pharmacoeconomics Brigham and Women's Hospital and Harvard Medical School Boston, MA Stephen B. Soumerai Drug Policy Research Group Department of Ambulatory Care and Prevention Harvard Medical School Boston, MA Malcolm Maclure School of Health Information Science University of Victoria Victoria, BC

References

  1. Anis A. Why is calling an ACE an ACE so controversial? Evaluating reference-based pricing in British Columbia [editorial]. CMAJ 2002; 166: 763-4.[Free Full Text]
  2. Schneeweiss S, Soumerai SB, Glynn RJ, Maclure M, Dormuth C, Walker AM. Impacts of reference pricing for ACE inhibitors on drug utilization. CMAJ 2002;166:737-48.[Abstract/Free Full Text]
  3. Schneeweiss S, Maclure M, Soumerai SB. Prescription duration after drug copay changes in the elderly: methodological aspects. J Am Geriatr Soc 2002;50:521-5.[Medline]
  4. Schneeweiss S, Walker AM, Glynn RJ, Maclure M, Dormuth C, Soumerai SB. Outcomes of reference drug pricing for angiotensin-converting enzyme inhibitors. N Engl J Med 2002;346:822-9.[Abstract/Free Full Text]
  5. British Columbia Ministry of Health Services: Pharmacare Trends 2000. Victoria, BC; 2001. p. 29.
  6. Adams AS, Soumerai SB, Ross-Degnan D. The case for a medicare drug coverage benefit: a critical review of the empirical evidence. Annu Rev Public Health 2001;22:49-61.[Medline]



This article has been cited by other articles:


Home page
 Health Aff (Millwood)Home page
S. B. Soumerai
Benefits And Risks Of Increasing Restrictions On Access To Costly Drugs In Medicaid
Health Aff., January 1, 2004; 23(1): 135 - 146.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schneeweiss, S.
Right arrow Articles by Maclure, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schneeweiss, S.
Right arrow Articles by Maclure, M.
Related Collections
Right arrow Other health policy
Right arrow Hypertension
Right arrow Other drug use